2026 Agenda: Day 2 - Tuesday 13 JanuaryTuesday, 13 January 2026 - PT (Pacific Time, GMT-08:00)

This session will discuss how regulatory reforms, ready access to financing, and a rapidly evolving innovation ecosystem are transforming Asia into a leading destination for biotech growth. Join investors and industry leaders to explore the opportunities and strategies shaping the future of biopharma in this dynamic market.

Even as breakthroughs in biotech and therapeutics accelerate, access and equity remain out of reach for many. With the new administration introducing policy changes, regulatory shifts, and funding priorities, the question looms: are these moves helping to expand healthcare access, or inadvertently creating new barriers? Join investors, industry leaders, and policymakers to explore how these developments are reshaping the landscape—and what strategies can drive meaningful, equitable change.

Explore how biotech companies can strategically navigate the complex European landscape – from clinical development through commercialisation. Gain actionable insights on how a coordinated, end-to-end approach from innovation through investment can unlock Europe’s full potential as a growth engine for biotech success. Why is Europe emerging as a prime destination for biotech investment and growth? How can end-to-end commercialisation strategies reduce barriers and accelerate time to market? What is the role of integrated European partners in driving efficiency, access, and investor confidence? Turn early innovation into sustainable returns through smart, pan-European expansion.

For biotechs operating on finite funding horizons and milestone-driven value inflection points, speed is survival. Research conducted by Parexel in late 2025 shines light into how accelerating clinical development requires more than operational efficiency—it demands strategic choices that de-risk development without compromising scientific or regulatory integrity. This fireside chat examines trends most significantly affecting the clinical development landscape today and in the next 3 to 5 years. Discussion also focuses on current strategies used by small and mid-sized biopharma to compress development timelines.